TYR and melanoma: As Bmal1 has been recently shown to participate as a positive prognostic marker and a putative biomarker for immunotherapy success in metastatic melanoma21, BMAL1 expression in tumor bulk and in tyrosinase-positive cells, i.e., melanoma cells, was investigated.